ASH Showcase for Clinical Progress in Hematology

This document is a technical report that outlines the ASH meeting's role as a premier venue for presenting early clinical signals and innovations in hematology. It describes how the meeting serves as a nexus for biopharma decision-makers, investors, and clinical stakeholders to gain visibility into programs that are redefining therapeutic boundaries. The report details the methodology used by Intelligencia AI to evaluate liquid oncology programs, including the Probability of Technical and Regulatory Success (PTRS) framework. The methodology consists of asset identification, PTRS-based ranking, expert validation, and watchlist selection. Each step is designed to ensure a comprehensive assessment of emerging candidates. The report also highlights the predictive power of this methodology, validated through prior conferences, where identified assets demonstrated positive clinical outcomes. Additionally, it discusses specific CAR-T therapies and their competitive positioning within the market, emphasizing the importance of rapid manufacturing and multi-antigen targeting in addressing challenges in hematologic malignancies.